Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The Centers for Medicare and Medicaid Services published the Medicare Drug Price Negotiation Program final rule, known as CMS-4215-F, in the Federal Register on November 9, 2026. The rule takes effect December 5, 2026, and governs every round of negotiations for drugs whose prices take effect in 2029 and in each year after that.

Until now the program has operated under a series of guidance documents, which are easier to issue but also easier to challenge in court. Converting those policies into a formal regulation gives the program a more durable legal foundation as lawsuits from pharmaceutical manufacturers continue to work through the federal courts.

Several provisions directly shape what Medicare enrollees pay at the pharmacy. Standalone Part D drug plans and Medicare Advantage drug plans are now required to include any selected drug with a Maximum Fair Price in effect on their formularies. What pharmacies receive for those drugs is capped at the Maximum Fair Price plus dispensing fees, a structure intended to pass negotiated savings through to patients at the counter.

The rule also creates a Temporary Floor for Small Biotech Drugs covering the 2029 and 2030 price years. Under that provision, CMS may not offer or accept a counteroffer below a specified minimum price for certain drugs from smaller manufacturers, a protection lawmakers built into the underlying statute. A separate provision addresses fixed-combination drugs, setting rules to prevent manufacturers from introducing a reformulated product that would restart the eligibility clock and delay negotiation.

CMS can select up to 20 drugs per cycle from Part D and Part B for each subsequent applicability year. The June 2026 proposed rule drew public comments before the agency finalized the policies published today.